Englander Institute for Precision Medicine

Bone-matrix mineralization dampens integrin-mediated mechanosignalling and metastatic progression in breast cancer.

TitleBone-matrix mineralization dampens integrin-mediated mechanosignalling and metastatic progression in breast cancer.
Publication TypeJournal Article
Year of Publication2023
AuthorsChoi S, Whitman MA, Shimpi AA, Sempertegui ND, Chiou AE, Druso JE, Verma A, Lux SC, Cheng Z, Paszek M, Elemento O, Estroff LA, Fischbach C
JournalNat Biomed Eng
Volume7
Issue11
Pagination1455-1472
Date Published2023 Nov
ISSN2157-846X
KeywordsAnimals, Bone Matrix, Breast Neoplasms, Calcification, Physiologic, Calcinosis, Collagen, Female, Humans, Integrins, Mammary Neoplasms, Animal, Mice
Abstract

In patients with breast cancer, lower bone mineral density increases the risk of bone metastasis. Although the relationship between bone-matrix mineralization and tumour-cell phenotype in breast cancer is not well understood, mineralization-induced rigidity is thought to drive metastatic progression via increased cell-adhesion forces. Here, by using collagen-based matrices with adjustable intrafibrillar mineralization, we show that, unexpectedly, matrix mineralization dampens integrin-mediated mechanosignalling and induces a less proliferative stem-cell-like phenotype in breast cancer cells. In mice with xenografted decellularized physiological bone matrices seeded with human breast tumour cells, the presence of bone mineral reduced tumour growth and upregulated a gene-expression signature that is associated with longer metastasis-free survival in patients with breast cancer. Our findings suggest that bone-matrix changes in osteogenic niches regulate metastatic progression in breast cancer and that in vitro models of bone metastasis should integrate organic and inorganic matrix components to mimic physiological and pathologic mineralization.

DOI10.1038/s41551-023-01077-3
Alternate JournalNat Biomed Eng
PubMed ID37550422
PubMed Central ID4723382
Grant ListRGP0016/2017 / / Human Frontier Science Program (HFSP) /
1U54CA210184 / / U.S. Department of Health & Human Services | NIH | National Cancer Institute (NCI) /
DGE-1650441 / / National Science Foundation (NSF) /

Weill Cornell Medicine Englander Institute for Precision Medicine 413 E 69th Street
Belfer Research Building
New York, NY 10021